Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
Daniel G. Stover(Harvard University), Nancy U. Lin(Dana-Farber Cancer Institute), Yaomin Xu(Vanderbilt University Medical Center), Yu Wang(Guizhou University), Aditya Bardia(UCLA Health), Carlos R. Gil Del Alcazar(Brigham and Women's Hospital), Rebecca Gelman(Dana-Farber Cancer Institute), Maxwell R. Lloyd(Beth Israel Deaconess Medical Center), Sara M. Tolaney(Harvard University), Eric P. Winer(University of Vermont), Hao Guo(Cancer Research And Biostatistics), Beth Overmoyer(Harvard University), Justin M. Balko(Vanderbilt University Medical Center), Franziska Michor(Dana-Farber Cancer Institute), Vivian Wang(University of Toronto), Qiong Xu(Vanderbilt University Medical Center), Jane Brock(Brigham and Women's Hospital), Kornélia Polyák(Dana-Farber Cancer Institute)
Cited by 150
Related Papers
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
|Nature reviews. Cancer|2009|3.3k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
A model for p53-induced apoptosis
|Nature|1997|2.5k